Nykode Therapeutics (NYKD) Corporate presentation summary

Strategic focus and technology platform

• Specializes in antigen-specific precision immunotherapy, leveraging proprietary APC-targeting technology for oncology and autoimmune diseases.

• Three core programs: lead asset abi-suva in randomized Ph2 for head & neck cancer, individualized cancer vaccine VB10.NEO, and a preclinical autoimmune tolerance platform.

• Modular technology enables delivery via DNA, mRNA, viral vectors, or recombinant proteins, with clinical data in oncology and preclinical data in autoimmune indications.

• Focused execution on prioritized assets with a strategy to reach key inflection points within 24 months.

• Strong financial position with cash runway into 2028-2029, supporting milestone achievement.

Oncology program highlights

• Abi-suva targets HPV16+ cancers, showing strong and durable clinical responses in multiple trials, with a Phase 2 RCT in 1L r/m HNSCC underway.

• Combination with checkpoint inhibitors in cervical cancer (C-02 trial) demonstrated improved ORR (29%) and mOS (24.7 months) over CPI monotherapy.

• Monotherapy efficacy observed in HSIL patients, with lesion regression and strong immune correlation.

• VB10.NEO individualized neoantigen therapy showed robust immune responses and manufacturing success in two late-stage basket trials.

• Proprietary NeoSELECT algorithm optimizes neoantigen selection, correlating with improved survival.

Autoimmune tolerance platform

• Antigen-specific immune tolerance (ASIT) platform aims to address root causes of autoimmune diseases, with preclinical data showing durable efficacy and immune regulation.

• Demonstrated efficacy in neurology (EAE/MS), metabolism (T1D), and dermatology (vitiligo, PV) models.

• AI/ML-driven multi-antigen construct design enhances therapeutic potential and manufacturing efficiency.

• Convenient delivery routes (i.v. and s.c.) support clinical translation.